{"product_id":"omega-3-fatty-acids-and-cancer-a-25-year-map-of-the-research-landscape-2000-2025","title":"Omega-3 Fatty Acids and Cancer: A 25-Year Map of the Research Landscape (2000–2025)","description":"\u003cp\u003eThis study mapped 25 years (2000–2025) of global research on omega-3 fatty acids in cancer, analyzing 2,917 publications from the Web of Science database and 7,380 from Scopus. The researchers found that this field has grown from basic laboratory science into a clinically focused area, with the United States, China, and Italy leading publication output. Major themes include inflammation, breast and colorectal cancer, and how omega-3s may help cancer treatment. The authors conclude that the field is shifting toward \"precision nutritional oncology,\" where omega-3s are tested as targeted, individualized additions to cancer therapy.\u003c\/p\u003e\n\n\u003ch1\u003eOmega-3 Fatty Acids and Cancer: A 25-Year Map of the Research Landscape (2000–2025)\u003c\/h1\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article explains how researchers used bibliometric analysis (a method of counting and mapping scientific publications) to understand the entire field of omega-3 and cancer research.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#why-it-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-are-omega3\"\u003eWhat Are Omega-3 Fatty Acids?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-goals\"\u003eWhat This Study Set Out to Do\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pub-trends\"\u003eKey Finding 1: Publication Trends Over 25 Years\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#countries\"\u003eKey Finding 2: Which Countries and Institutions Led the Field\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#journals\"\u003eKey Finding 3: The Journals That Published This Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#citation-bursts\"\u003eKey Finding 4: The Most Influential Papers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#themes\"\u003eKey Finding 5: Main Research Themes and Hotspots\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-trials\"\u003eKey Finding 6: The Clinical Trial Landscape\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for the Future\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eThe review mapped over 2,900 omega-3 and cancer publications from 2000 to 2025, showing growth into a stable clinical research field.\u003c\/li\u003e\n\u003cli\u003eThe United States, China, and Italy led publication output; breast and colorectal cancers were the most studied tumor types.\u003c\/li\u003e\n\u003cli\u003eClinical trials mainly test omega-3s as supportive cancer therapy, often combined with chemotherapy, radiation, or surgery.\u003c\/li\u003e\n\u003cli\u003eMost research explores antitumor mechanisms, inflammation, and whether omega-3 intake or blood levels alter cancer risk.\u003c\/li\u003e\n\u003cli\u003eThe field is moving toward precision nutritional oncology, tailoring omega-3 dose, form, and timing to individual cancer patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"why-it-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eCancer remains one of the world's most serious public health challenges. According to the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), roughly 19.965 million new cancer cases were diagnosed worldwide in 2022 — that's about 1 in 400 people on Earth that year. The disease caused about 9.737 million deaths, or approximately 1 in 820 people.\u003c\/p\u003e\n\n\u003cp\u003eThe future looks even more daunting. By 2050, researchers project that the number of newly diagnosed cancer cases worldwide will exceed 35 million.\u003c\/p\u003e\n\n\u003cp\u003eCurrent treatments include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Yet these approaches have real limits. Chemotherapy and targeted drugs often stop working because tumors develop drug resistance, which is a major cause of treatment failure and cancer recurrence. Anticancer drugs also frequently cause severe side effects, including fatigue, nausea and vomiting, loss of appetite, nerve damage (neurotoxicity), and blood clots (thrombosis). These reactions can seriously damage a patient's quality of life.\u003c\/p\u003e\n\n\u003cp\u003eThis is why doctors and scientists are urgently looking for \u003cstrong\u003eadjunctive strategies\u003c\/strong\u003e (extra treatments that work alongside standard cancer care) to reduce side effects and improve outcomes. Among these, nutritional interventions with anti-inflammatory and immune-modulating properties have attracted growing attention. Omega-3 polyunsaturated fatty acids sit at the center of this interest.\u003c\/p\u003e\n\n\u003ch2 id=\"what-are-omega3\"\u003eWhat Are Omega-3 Fatty Acids?\u003c\/h2\u003e\n\n\u003cp\u003eOmega-3 polyunsaturated fatty acids (PUFAs) are a family of unsaturated fats. Their name comes from their chemistry: the first double bond in their carbon chain appears at the third carbon atom from the methyl (omega) end of the molecule. That small structural detail changes how these fats behave in the human body.\u003c\/p\u003e\n\n\u003cp\u003eIn nutrition and cancer research, three omega-3s matter most:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlpha-linolenic acid (ALA)\u003c\/strong\u003e — an essential fatty acid your body cannot make. You must get it through diet. It comes mainly from nuts and plant oils, including chia seed oil, walnut oil, flaxseed oil, and hemp seed oil.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEicosapentaenoic acid (EPA)\u003c\/strong\u003e — a longer-chain omega-3 found mainly in fatty fish, seafood, and algal oils.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDocosahexaenoic acid (DHA)\u003c\/strong\u003e — also found in fatty fish, seafood, and algal oils; it is especially important for brain and eye tissue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eYour body can convert ALA into EPA and DHA through a series of chemical reactions, but this conversion is inefficient. That's why eating fatty fish directly remains the main way humans get meaningful amounts of EPA and DHA.\u003c\/p\u003e\n\n\u003cp\u003eOmega-3s have an impressive resume of health effects. In the cardiovascular system, they act as anti-inflammatory, vasodilatory (blood vessel-widening), antiarrhythmic (heart rhythm-stabilizing), antihypertensive (blood pressure-lowering), anticoagulant (clot-preventing), and triglyceride-lowering agents. In the nervous system, they are structural components of nerve cell membranes, where they support membrane fluidity, help regulate oxidative stress, dampen inflammation, and protect neurons. During pregnancy, adequate omega-3 intake supports fetal brain and retinal development and reduces the risk of adverse pregnancy outcomes. Omega-3s have also been studied in chronic inflammatory conditions such as asthma, psoriasis, inflammatory bowel disease, rheumatoid arthritis, and diabetes. Some emerging evidence even links omega-3s to biological aging through effects on inflammation and epigenetic regulation (chemical changes that switch genes on or off).\u003c\/p\u003e\n\n\u003cp\u003eWhy might this matter for cancer? Cancer development is closely tied to chronic inflammation, oxidative stress, metabolic disruption, immune dysfunction, epigenetic changes, and altered cell signaling. Omega-3s speak to nearly all of these processes. Laboratory (preclinical) studies suggest omega-3s may slow tumor growth through several mechanisms — inducing apoptosis (programmed cell death), regulating lipid (fat) metabolism, modifying epigenetic signals, modulating immune responses, and remodeling the tumor microenvironment (the surrounding tissue that supports or suppresses tumor growth). Clinical studies have explored whether omega-3s can improve quality of life in patients with cancer cachexia (severe weight loss and muscle wasting), enhance chemotherapy sensitivity, and reduce treatment-related side effects.\u003c\/p\u003e\n\n\u003ch2 id=\"study-goals\"\u003eWhat This Study Set Out to Do\u003c\/h2\u003e\n\n\u003cp\u003eDespite all this research, the omega-3-and-cancer field is fragmented. Studies span basic mechanisms, population epidemiology, biomarker assessments, nutritional interventions, perioperative immunonutrition (giving immune-supporting nutrition around the time of surgery), and combinations with anticancer drugs.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers wanted to step back and see the whole picture. They used a technique called \u003cstrong\u003ebibliometrics\u003c\/strong\u003e — quantitative analysis of publications, citations, and keyword patterns — to systematically map the field from January 2000 to December 2025. Their goal was to identify research trends, knowledge hotspots, and emerging themes, and ultimately to provide evidence-based direction for future laboratory research, nutritional oncology, and clinical practice.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe research team searched three major scientific databases on December 15, 2025: the Web of Science Core Collection (WoSCC), Scopus, and PubMed.\u003c\/p\u003e\n\n\u003cp\u003eTheir search strategy combined two concept groups. The cancer side included terms like \"cancer,\" \"tumor,\" \"oncology,\" \"neoplasm,\" and \"carcinoma.\" The omega-3 side included \"omega-3 PUFA,\" \"omega-3 fatty acid,\" \"n-3 PUFA,\" and related spellings. They limited results to English-language articles and reviews published between 2000 and 2025. For PubMed, they additionally filtered for clinical trials.\u003c\/p\u003e\n\n\u003cp\u003eAfter removing duplicates, the WoSCC database yielded \u003cstrong\u003e2,917 publications\u003c\/strong\u003e. Scopus yielded \u003cstrong\u003e7,380 distinct records\u003c\/strong\u003e. Because WoSCC and Scopus format data differently, the researchers analyzed each database separately to avoid information loss. They treated WoSCC as the primary source for detailed analyses because of its standardized records and compatibility with bibliometric software. Scopus data served as a complement, and its keyword analyses appear in the article's supplementary materials.\u003c\/p\u003e\n\n\u003cp\u003eFor the analysis, they used four main software tools:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eR software (version 4.5.2)\u003c\/strong\u003e with the bibliometrix package (version 4.0) — for general bibliometric calculations\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVOSviewer (version 1.6.20)\u003c\/strong\u003e — for mapping collaboration networks between countries and institutions, and for journal\/keyword patterns\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCiteSpace (version 6.4.R1)\u003c\/strong\u003e — for detecting citation bursts (papers that suddenly receive intense attention)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrigin 2018\u003c\/strong\u003e — for evaluating annual publication trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTwo researchers independently performed the data collection and analysis to confirm accuracy and reliability, with a third consulted to resolve any disagreements. Journal impact factors (which measure how often articles in a journal are cited) came from the 2024 edition of the Journal Citation Reports.\u003c\/p\u003e\n\n\u003cp\u003eSome thresholds were set to keep the maps readable. Countries had to contribute at least 5 documents, organizations at least 10 papers, journals at least 300 citations, and keywords had to appear at least 28 times (in WoSCC) or 23 times (in Scopus). Generic search terms like \"omega-3 PUFAs\" and \"cancer\" were deliberately excluded from keyword maps. The researchers reasoned that these words would appear so often — simply because of the search strategy itself — that they would drown out meaningful thematic signals.\u003c\/p\u003e\n\n\u003ch2 id=\"pub-trends\"\u003eKey Finding 1: Publication Trends Over 25 Years\u003c\/h2\u003e\n\n\u003cp\u003eBetween 2000 and 2025, the annual number of publications on omega-3s and cancer increased steadily over time. The field then reached a plateau and experienced a slight decline in the most recent years. There was a notable peak around \u003cstrong\u003e2018\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBoth databases told the same story. The WoSCC data showed 2,917 total publications; the Scopus data showed 7,380. The researchers interpreted this pattern to mean that omega-3 cancer research has received sustained attention and settled into a stable research field — not a passing fad.\u003c\/p\u003e\n\n\u003ch2 id=\"countries\"\u003eKey Finding 2: Which Countries and Institutions Led the Field\u003c\/h2\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eUnited States\u003c\/strong\u003e emerged as the clear global leader in omega-3 cancer research, contributing 819 publications — about 28.1% of corresponding-author papers. \u003cstrong\u003eChina\u003c\/strong\u003e ranked second with 391 publications (13.4%), and \u003cstrong\u003eItaly\u003c\/strong\u003e third with 171 (5.9%). Canada (170), Japan (133), and the United Kingdom (122) followed closely.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also tracked \u003cstrong\u003emultiple country publications (MCPs)\u003c\/strong\u003e — papers written by authors from more than one country. The United States and China produced similar rates of international collaboration: 18.6% and 17.9% of their papers, respectively. But Denmark, Germany, and Korea, despite publishing fewer papers overall, achieved notably higher collaboration rates of \u003cstrong\u003e45.5%, 36.9%, and 31.5%\u003c\/strong\u003e, respectively.\u003c\/p\u003e\n\n\u003cp\u003eThe table below shows the full country-by-country breakdown from the study:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003eCountry\u003c\/th\u003e\n\u003cth\u003eArticles\u003c\/th\u003e\n\u003cth\u003eSingle-Country Papers (SCP)\u003c\/th\u003e\n\u003cth\u003eMulti-Country Papers (MCP)\u003c\/th\u003e\n\u003cth\u003eFrequency (%)\u003c\/th\u003e\n\u003cth\u003eMCP Rate (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eUSA\u003c\/td\u003e\n\u003ctd\u003e819\u003c\/td\u003e\n\u003ctd\u003e667\u003c\/td\u003e\n\u003ctd\u003e152\u003c\/td\u003e\n\u003ctd\u003e28.1\u003c\/td\u003e\n\u003ctd\u003e18.6\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003e391\u003c\/td\u003e\n\u003ctd\u003e321\u003c\/td\u003e\n\u003ctd\u003e70\u003c\/td\u003e\n\u003ctd\u003e13.4\u003c\/td\u003e\n\u003ctd\u003e17.9\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eItaly\u003c\/td\u003e\n\u003ctd\u003e171\u003c\/td\u003e\n\u003ctd\u003e137\u003c\/td\u003e\n\u003ctd\u003e34\u003c\/td\u003e\n\u003ctd\u003e5.9\u003c\/td\u003e\n\u003ctd\u003e19.9\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003ctd\u003e170\u003c\/td\u003e\n\u003ctd\u003e132\u003c\/td\u003e\n\u003ctd\u003e38\u003c\/td\u003e\n\u003ctd\u003e5.8\u003c\/td\u003e\n\u003ctd\u003e22.4\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003e133\u003c\/td\u003e\n\u003ctd\u003e122\u003c\/td\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003ctd\u003e4.6\u003c\/td\u003e\n\u003ctd\u003e8.3\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eUnited Kingdom\u003c\/td\u003e\n\u003ctd\u003e122\u003c\/td\u003e\n\u003ctd\u003e87\u003c\/td\u003e\n\u003ctd\u003e35\u003c\/td\u003e\n\u003ctd\u003e4.2\u003c\/td\u003e\n\u003ctd\u003e28.7\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eKorea\u003c\/td\u003e\n\u003ctd\u003e92\u003c\/td\u003e\n\u003ctd\u003e63\u003c\/td\u003e\n\u003ctd\u003e29\u003c\/td\u003e\n\u003ctd\u003e3.2\u003c\/td\u003e\n\u003ctd\u003e31.5\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eFrance\u003c\/td\u003e\n\u003ctd\u003e91\u003c\/td\u003e\n\u003ctd\u003e68\u003c\/td\u003e\n\u003ctd\u003e23\u003c\/td\u003e\n\u003ctd\u003e3.1\u003c\/td\u003e\n\u003ctd\u003e25.3\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eBrazil\u003c\/td\u003e\n\u003ctd\u003e84\u003c\/td\u003e\n\u003ctd\u003e66\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003ctd\u003e2.9\u003c\/td\u003e\n\u003ctd\u003e21.4\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eSpain\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003ctd\u003e57\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003e2.5\u003c\/td\u003e\n\u003ctd\u003e20.8\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eGermany\u003c\/td\u003e\n\u003ctd\u003e65\u003c\/td\u003e\n\u003ctd\u003e41\u003c\/td\u003e\n\u003ctd\u003e24\u003c\/td\u003e\n\u003ctd\u003e2.2\u003c\/td\u003e\n\u003ctd\u003e36.9\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eAustralia\u003c\/td\u003e\n\u003ctd\u003e64\u003c\/td\u003e\n\u003ctd\u003e47\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003ctd\u003e2.2\u003c\/td\u003e\n\u003ctd\u003e26.6\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eIndia\u003c\/td\u003e\n\u003ctd\u003e63\u003c\/td\u003e\n\u003ctd\u003e49\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003ctd\u003e2.2\u003c\/td\u003e\n\u003ctd\u003e22.2\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eIran\u003c\/td\u003e\n\u003ctd\u003e60\u003c\/td\u003e\n\u003ctd\u003e44\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e2.1\u003c\/td\u003e\n\u003ctd\u003e26.7\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNorway\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003ctd\u003e32\u003c\/td\u003e\n\u003ctd\u003e13\u003c\/td\u003e\n\u003ctd\u003e1.5\u003c\/td\u003e\n\u003ctd\u003e28.9\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eDenmark\u003c\/td\u003e\n\u003ctd\u003e44\u003c\/td\u003e\n\u003ctd\u003e24\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003ctd\u003e1.5\u003c\/td\u003e\n\u003ctd\u003e45.5\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNetherlands\u003c\/td\u003e\n\u003ctd\u003e40\u003c\/td\u003e\n\u003ctd\u003e26\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003ctd\u003e1.4\u003c\/td\u003e\n\u003ctd\u003e35.0\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003ePoland\u003c\/td\u003e\n\u003ctd\u003e40\u003c\/td\u003e\n\u003ctd\u003e36\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003e1.4\u003c\/td\u003e\n\u003ctd\u003e10.0\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eEgypt\u003c\/td\u003e\n\u003ctd\u003e29\u003c\/td\u003e\n\u003ctd\u003e22\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003e1.0\u003c\/td\u003e\n\u003ctd\u003e24.1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eSweden\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003ctd\u003e0.9\u003c\/td\u003e\n\u003ctd\u003e36.0\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003ePortugal\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003e0.7\u003c\/td\u003e\n\u003ctd\u003e20.0\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eGreece\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003ctd\u003e13\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003e0.6\u003c\/td\u003e\n\u003ctd\u003e23.5\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eMexico\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003e0.5\u003c\/td\u003e\n\u003ctd\u003e31.3\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eSwitzerland\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003e0.5\u003c\/td\u003e\n\u003ctd\u003e31.3\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eTurkey\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003e0.5\u003c\/td\u003e\n\u003ctd\u003e25.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe United States also maintained the most extensive international collaboration network — the map showed strong links between US researchers and teams across Europe, Asia, and the Americas.\u003c\/p\u003e\n\n\u003cp\u003eAt the institutional level, core contributing centers emerged. Harvard University led with 88 publications, followed by Brigham and Women's Hospital (61), Texas A\u0026amp;M University (58), Harvard Medical School (57), and the University of Alberta (55). Other active institutions included Massachusetts General Hospital (48), the Harvard T.H. Chan School of Public Health (45), the University of Southampton (38), the University of Illinois (36), and The Ohio State University (34). The study's conclusion was that influence in this field comes not just from publishing many papers but also from being deeply connected in collaborative networks.\u003c\/p\u003e\n\n\u003ch2 id=\"journals\"\u003eKey Finding 3: The Journals That Published This Research\u003c\/h2\u003e\n\n\u003cp\u003eAll 2,917 WoSCC publications appeared across \u003cstrong\u003e869 different journals\u003c\/strong\u003e. That's a highly scattered field — no single journal dominates.\u003c\/p\u003e\n\n\u003cp\u003eThe most productive journals by article count were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNutrients\u003c\/strong\u003e: 98 articles — impact factor (IF) 5.0\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNutrition and Cancer-An International Journal\u003c\/strong\u003e: 83 articles — IF 2.4\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal of Nutritional Biochemistry\u003c\/strong\u003e: 66 articles — IF 4.9\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBut publication count tells only half the story. Citation counts reveal which journals carry the most weight. By citations received, the leaders were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAmerican Journal of Clinical Nutrition\u003c\/strong\u003e: 5,299 citations (IF 6.9, from 50 documents)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer Research\u003c\/strong\u003e: 3,376 citations (IF 16.9, from 19 documents)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal of Nutrition\u003c\/strong\u003e: 3,177 citations (IF 3.8, from 59 documents)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal of Biological Chemistry\u003c\/strong\u003e: 2,813 citations (IF 3.9, from 7 documents)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA co-citation analysis (which looks at which journals are cited together) identified the American Journal of Clinical Nutrition, Cancer Research, International Journal of Cancer, and Nutrients as the core journals forming the intellectual backbone of this field.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers noted a revealing gap: relatively few papers appeared in the highest-impact journals. They called this a \"publication gap in high-impact journals\" and framed it as both a weakness and an opportunity. Raising the methodological quality of future studies could help the field earn space in more prestigious venues.\u003c\/p\u003e\n\n\u003ch2 id=\"citation-bursts\"\u003eKey Finding 4: The Most Influential Papers\u003c\/h2\u003e\n\n\u003cp\u003eCitation bursts are periods when a particular paper suddenly gets cited far more often than usual. They act like seismographs for scientific attention. The researchers identified the \u003cstrong\u003e25 strongest citation bursts\u003c\/strong\u003e in omega-3 cancer research.\u003c\/p\u003e\n\n\u003cp\u003eThe three most intense bursts were:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries\"\u003c\/strong\u003e — burst strength 33.61\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Dietary Long-Chain Omega-3 PUFAs for the Prevention of Cancer: A Review of Potential Mechanisms\"\u003c\/strong\u003e — burst strength 33.11\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Effects of Omega-3 Fatty Acids on Cancer Risk: A Systematic Review\"\u003c\/strong\u003e — burst strength 25.24\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe most recent papers experiencing rising citation activity point to where the field is heading. These include \u003cstrong\u003e\"Omega-3 Fatty Acids and Inflammatory Processes: From Molecules to Man,\"\u003c\/strong\u003e \u003cstrong\u003e\"Protective Effects of Omega-3 Fatty Acids in Cancer-Related Complications,\"\u003c\/strong\u003e and the GLOBOCAN 2020 statistics paper.\u003c\/p\u003e\n\n\u003cp\u003eLooking across all the burst patterns, the researchers identified three core research directions:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMulti-target anticancer mechanisms\u003c\/strong\u003e — how omega-3s work at the molecular level through lipid metabolism, inflammatory signaling pathways, and programmed cell death (apoptosis)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEpidemiological significance\u003c\/strong\u003e — how dietary omega-3 intake and blood\/tissue levels relate to the risk of cancer and other chronic diseases, with fatty acid balance viewed as a key dietary factor in disease risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTranslational application in clinical cancer care\u003c\/strong\u003e — how omega-3s can be used to support patients undergoing cancer treatment\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"themes\"\u003eKey Finding 5: Main Research Themes and Hotspots\u003c\/h2\u003e\n\n\u003cp\u003eKeyword co-occurrence analysis (which counts how often terms appear together in papers) revealed the intellectual terrain of the field. The major research themes were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\"inflammation\"\u003c\/li\u003e\n  \u003cli\u003e\"breast cancer\"\u003c\/li\u003e\n  \u003cli\u003e\"risk\"\u003c\/li\u003e\n  \u003cli\u003e\"colorectal cancer\"\u003c\/li\u003e\n  \u003cli\u003e\"expression\" (referring to gene or protein expression in laboratory studies)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAntitumor mechanisms\u003c\/strong\u003e were the dominant focus. In plain terms, the largest share of research investigated how omega-3s attack cancer at the cellular level.\u003c\/p\u003e\n\n\u003cp\u003eA second major theme connected \u003cstrong\u003edietary omega-3 intake and biomarker status\u003c\/strong\u003e (objective measures of omega-3 levels in the body) with cancer risk and cancer progression. These studies ask a practical question: does what you eat — or what's measurable in your blood — change your cancer risk?\u003c\/p\u003e\n\n\u003cp\u003eA third, rapidly growing theme was the \u003cstrong\u003eapplication of omega-3s in actual clinical antitumor therapy\u003c\/strong\u003e. The keyword data suggest this translational direction has emerged as a prominent hotspot in recent years.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-trials\"\u003eKey Finding 6: The Clinical Trial Landscape\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers also screened PubMed for clinical trial records published between 2000 and 2025, using the same search logic. Two independent reviewers examined titles, abstracts, and keywords to identify trials genuinely testing omega-3s against cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe clinical trial picture showed two clear patterns. First, trials have \u003cstrong\u003eprimarily focused on antitumor applications\u003c\/strong\u003e — meaning most trials ask whether omega-3s can fight cancer itself or support cancer treatment, rather than just prevent the disease. Second, there is a clear \u003cstrong\u003etendency toward combined treatment strategies\u003c\/strong\u003e — omega-3s tested alongside chemotherapy, radiation, surgery, or other therapies.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis is a mapping study, not a clinical trial, so it does not directly prove that omega-3s help any particular patient. But the patterns it reveals carry practical meaning.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the field has clearly moved past the question of whether omega-3s might fight cancer in a petri dish. Funding, publications, and clinical trials are now concentrated on \u003cstrong\u003ereal-world use\u003c\/strong\u003e: omega-3s as supportive care, as chemotherapy sensitizers, and as an anti-inflammatory tool in patients living with cancer.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the emphasis on \"inflammation,\" \"breast cancer,\" \"colorectal cancer,\" and \"risk\" tells patients that the most mature evidence clusters in specific areas. Breast and colorectal cancers are the two tumor types where omega-3 research has accumulated the most depth. For patients with these cancers, discussions about omega-3 supplementation are more likely to be grounded in solid data.\u003c\/p\u003e\n\n\u003cp\u003eThird, the movement toward \"precision nutritional oncology\" means the future is not about giving everyone the same fish oil pill. The authors describe a framework that combines molecular mechanisms, objective exposure biomarkers (measuring actual omega-3 levels in blood or tissues rather than relying on dietary memory), and clinical intervention strategies. In this future, a patient's omega-3 dose, form (EPA-dominant vs. DHA-dominant vs. ALA), and timing of treatment would be tailored to their specific cancer type, treatment plan, and nutritional status.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers' conclusions are about the structure of science, but the purpose is ultimately patient care: identify which patients actually benefit, at what dose, for how long, and during which phase of treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eSeveral important limitations apply to this bibliometric study.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBibliometric studies describe the literature; they do not test treatments.\u003c\/strong\u003e The citation counts, keyword maps, and burst analyses show where scientists have focused their attention, not whether omega-3s actually improve cancer outcomes. High research activity can reflect funding trends, scientific fashion, or controversy just as easily as it reflects proven benefit.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe search was restricted to English-language articles and reviews.\u003c\/strong\u003e Important work published in Chinese, Spanish, German, or other languages would have been missed. Given that China is the second-largest publishing country in this field, English-only searching could skew the picture.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe two largest databases could not be merged\u003c\/strong\u003e because of format differences. The researchers analyzed WoSCC and Scopus separately to avoid losing data, but this means the headline numbers (2,917 and 7,380) come from two parallel universes rather than one integrated dataset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe citation burst method lags reality.\u003c\/strong\u003e The three strongest bursts all related to papers published around 2020 or earlier. Very recent work, however important, has not yet had time to accumulate citations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeyword exclusion rules shaped the results.\u003c\/strong\u003e The researchers removed generic terms like \"omega-3 PUFAs\" and \"cancer\" and set high frequency thresholds. Different thresholds could have produced different thematic maps.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal impact factors measure journals, not individual articles.\u003c\/strong\u003e A paper in a low-impact journal may be practice-changing, while a paper in a high-impact journal may be ignored.\u003c\/p\u003e\n\n\u003cp\u003eFinally, affiliation analysis tracks where authors are based, not where the research was conducted or funded. Institutional prestige (like Harvard's eight-affiliation presence in the top 20) can be amplified by well-resourced centers that host many international collaborators.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for the Future\u003c\/h2\u003e\n\n\u003cp\u003eBased on the gaps they identified, the authors recommend that future research focus on five key areas:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandardized exposure assessment\u003c\/strong\u003e — develop and adopt consistent methods for measuring omega-3 intake and tissue levels so studies can be compared directly\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDose–response modeling\u003c\/strong\u003e — define how much omega-3 is needed to produce a biological or clinical effect, and whether more is better\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient stratification\u003c\/strong\u003e — identify which subgroups of patients (by cancer type, genetics, treatment regimen, or nutritional status) are most likely to benefit\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClinically meaningful endpoints\u003c\/strong\u003e — measure outcomes that matter to patients, like survival, quality of life, and treatment tolerance, not just laboratory markers\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrecision trial design\u003c\/strong\u003e — define target populations, optimal formulations and dosages, and appropriate intervention windows (for example, before surgery, during chemotherapy, or after treatment concludes)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn their own words: research on omega-3 PUFAs in oncology is \"progressively shifting from mechanistic exploration toward clinically oriented and translational applications.\" The emerging vision is a precision-oriented nutritional oncology, where omega-3s are deployed deliberately — to the right patient, at the right dose, at the right time.\u003c\/p\u003e\n\n\u003cp\u003eWhat does this mean for patients reading this today? Speak with your oncology care team before starting any omega-3 supplement. The evidence base is promising but still maturing, and the unanswered questions in this map — dose, timing, and who benefits most — are exactly the questions your doctor needs answered before making a recommendation.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eDoes omega-3 really help fight cancer, based on this 25-year research review?\u003c\/h3\u003e\n\u003cp\u003eIn laboratory studies, omega-3s slowed tumor growth through several mechanisms, including inducing cell death and reducing inflammation. Clinical trials mainly explore omega-3s as supportive care alongside chemotherapy, radiation, or surgery. This mapping study describes research patterns; it does not prove that omega-3s improve outcomes for any specific patient.\u003c\/p\u003e\n\u003ch3\u003eWhich cancers had the most omega-3 research, and should patients with other cancers use omega-3s?\u003c\/h3\u003e\n\u003cp\u003eThe most mature evidence clusters around breast cancer and colorectal cancer. Other cancer types have less published research. This article does not say whether omega-3s help other cancers. Patients should ask their oncology team about evidence for their specific cancer type before considering omega-3 supplements.\u003c\/p\u003e\n\u003ch3\u003eI am having chemotherapy. Is it safe to take omega-3 supplements?\u003c\/h3\u003e\n\u003cp\u003eOmega-3s are being tested as chemotherapy sensitizers and to reduce side effects, but optimal dose, timing, and which patients benefit remain unanswered questions. This review did not establish safety or effectiveness. Consult your oncology care team before starting any supplement, especially during active cancer treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat does 'precision nutritional oncology' mean for patients?\u003c\/h3\u003e\n\u003cp\u003eInstead of giving everyone the same fish oil pill, future care would tailor omega-3 dose, form, and timing to a patient's cancer type, treatment plan, and measured blood or tissue omega-3 levels. This approach is still emerging and not yet a standard part of patient care.\u003c\/p\u003e\n\u003ch3\u003eIs omega-3 meant to prevent cancer or treat it?\u003c\/h3\u003e\n\u003cp\u003eThe review found that clinical trials have primarily focused on antitumor applications, meaning using omega-3s to fight cancer or support cancer treatment, rather than only preventing disease. Many trials test omega-3s combined with chemotherapy, radiation, or surgery. More research is still needed.\u003c\/p\u003e\n\u003ch3\u003eWhat were the main limitations of this omega-3 cancer research overview?\u003c\/h3\u003e\n\u003cp\u003eThis was a bibliometric study, meaning it mapped publications and citations; it did not test treatments. The search was English-only, separated two databases, and citation bursts lag behind new work. High research activity can reflect funding trends, not proven benefit. Always interpret findings with your doctor.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before taking omega-3 supplements during cancer treatment?\u003c\/h3\u003e\n\u003cp\u003eNo single answer applies to everyone. Because omega-3 research is still maturing, the right dose, form (EPA vs DHA vs ALA), and timing during chemotherapy, radiation, or surgery remain unsettled. The strongest evidence clusters around breast and colorectal cancer, but even there the decision to supplement is not precision-based yet. Before taking omega-3s during cancer treatment, a second opinion can help clarify whether supplementation is appropriate for your specific cancer type, treatment phase, and nutritional status. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article:\u003c\/strong\u003e \"Bibliometric and visual analysis of omega-3 polyunsaturated fatty acids in cancer research (2000–2025)\"\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Gao C, Li Y, Su H, Yu X, Lu X, Liang X, Tao F, Duan X.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Clinical Nutrition, Department of Oncology, and Department of Radiation Oncology, Liaocheng People's Hospital, Liaocheng, China\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Nutrition, Volume 13, Article 1818038\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e July 8, 2026\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fnut.2026.1818038\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Systematic Review (open access, licensed under CC BY)\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Always consult your healthcare provider about diet and supplement decisions, especially during cancer treatment.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576811896988,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ja\/products\/omega-3-fatty-acids-and-cancer-a-25-year-map-of-the-research-landscape-2000-2025","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}